191 related articles for article (PubMed ID: 37172199)
41. Identification of the protein kinases that activate the E3 ubiquitin ligase Pellino 1 in the innate immune system.
Goh ET; Arthur JS; Cheung PC; Akira S; Toth R; Cohen P
Biochem J; 2012 Jan; 441(1):339-46. PubMed ID: 22007846
[TBL] [Abstract][Full Text] [Related]
42. Inhibition of IRAK4 kinase activity improves ethanol-induced liver injury in mice.
Wang H; Zhou H; Zhang Q; Poulsen KL; Taylor V; McMullen MR; Czarnecki D; Dasarathy D; Yu M; Liao Y; Allende DS; Chen X; Hong L; Zhao J; Yang J; Nagy LE; Li X
J Hepatol; 2020 Dec; 73(6):1470-1481. PubMed ID: 32682051
[TBL] [Abstract][Full Text] [Related]
43. Splicing factor mutations in the myelodysplastic syndromes: Role of key aberrantly spliced genes in disease pathophysiology and treatment.
Pellagatti A; Boultwood J
Adv Biol Regul; 2023 Jan; 87():100920. PubMed ID: 36216757
[TBL] [Abstract][Full Text] [Related]
44. CBL exon 8/9 mutants activate the FLT3 pathway and cluster in core binding factor/11q deletion acute myeloid leukemia/myelodysplastic syndrome subtypes.
Reindl C; Quentmeier H; Petropoulos K; Greif PA; Benthaus T; Argiropoulos B; Mellert G; Vempati S; Duyster J; Buske C; Bohlander SK; Humphries KR; Hiddemann W; Spiekermann K
Clin Cancer Res; 2009 Apr; 15(7):2238-47. PubMed ID: 19276253
[TBL] [Abstract][Full Text] [Related]
45. Interleukin-1 Receptor-Associated Kinase 1/4 as a Novel Target for Inhibiting Neointimal Formation After Carotid Balloon Injury.
Bai S; Li D; Zhou Z; Cao J; Xu T; Zhang X; Wang Y; Guo J; Zhang Y
J Atheroscler Thromb; 2015; 22(12):1317-37. PubMed ID: 26310493
[TBL] [Abstract][Full Text] [Related]
46. Overcoming adaptive therapy resistance in AML by targeting immune response pathways.
Melgar K; Walker MM; Jones LM; Bolanos LC; Hueneman K; Wunderlich M; Jiang JK; Wilson KM; Zhang X; Sutter P; Wang A; Xu X; Choi K; Tawa G; Lorimer D; Abendroth J; O'Brien E; Hoyt SB; Berman E; Famulare CA; Mulloy JC; Levine RL; Perentesis JP; Thomas CJ; Starczynowski DT
Sci Transl Med; 2019 Sep; 11(508):. PubMed ID: 31484791
[TBL] [Abstract][Full Text] [Related]
47. Comprehensive RNAi-based screening of human and mouse TLR pathways identifies species-specific preferences in signaling protein use.
Sun J; Li N; Oh KS; Dutta B; Vayttaden SJ; Lin B; Ebert TS; De Nardo D; Davis J; Bagirzadeh R; Lounsbury NW; Pasare C; Latz E; Hornung V; Fraser ID
Sci Signal; 2016 Jan; 9(409):ra3. PubMed ID: 26732763
[TBL] [Abstract][Full Text] [Related]
48. Upregulated IRAK1 and IRAK4 promoting the production of IFN-γ and IL-17 in Behcet's disease.
Sun M; Yang P; Yang Y; Ye J
Int Ophthalmol; 2018 Oct; 38(5):1947-1953. PubMed ID: 28780618
[TBL] [Abstract][Full Text] [Related]
49. Immune complex-mediated cell activation from systemic lupus erythematosus and rheumatoid arthritis patients elaborate different requirements for IRAK1/4 kinase activity across human cell types.
Chiang EY; Yu X; Grogan JL
J Immunol; 2011 Jan; 186(2):1279-88. PubMed ID: 21160042
[TBL] [Abstract][Full Text] [Related]
50. The IRAK4 scaffold integrates TLR4-driven TRIF and MYD88 signaling pathways.
Pereira M; Durso DF; Bryant CE; Kurt-Jones EA; Silverman N; Golenbock DT; Gazzinelli RT
Cell Rep; 2022 Aug; 40(7):111225. PubMed ID: 35977521
[TBL] [Abstract][Full Text] [Related]
51. IRAK1-regulated IFN-γ signaling induces MDSC to facilitate immune evasion in FGFR1-driven hematological malignancies.
Cai B; Liu Y; Chong Y; Zhang H; Matsunaga A; Fang X; Pacholczyk R; Zhou G; Cowell JK; Hu T
Mol Cancer; 2021 Dec; 20(1):165. PubMed ID: 34906138
[TBL] [Abstract][Full Text] [Related]
52. IRAK-4 inhibition: emavusertib for the treatment of lymphoid and myeloid malignancies.
Parrondo RD; Iqbal M; Von Roemeling R; Von Roemeling C; Tun HW
Front Immunol; 2023; 14():1239082. PubMed ID: 37954584
[TBL] [Abstract][Full Text] [Related]
53. The role of interleukin-1 receptor-associated kinases in Vogt-Koyanagi-Harada disease.
Sun M; Yang P; Du L; Yang Y; Ye J
PLoS One; 2014; 9(4):e93214. PubMed ID: 24690905
[TBL] [Abstract][Full Text] [Related]
54. Epigenetic priming with decitabine followed by low dose idarubicin and cytarabine in acute myeloid leukemia evolving from myelodysplastic syndromes and higher-risk myelodysplastic syndromes: a prospective multicenter single-arm trial.
Zhou X; Mei C; Zhang J; Lu Y; Lan J; Lin S; Zhang Y; Kuang Y; Ren Y; Ma L; Wei J; Ye L; Xu W; Li K; Lu C; Jin J; Tong H
Hematol Oncol; 2020 Oct; 38(4):531-540. PubMed ID: 32469434
[TBL] [Abstract][Full Text] [Related]
55. Antisense STAT3 inhibitor decreases viability of myelodysplastic and leukemic stem cells.
Shastri A; Choudhary G; Teixeira M; Gordon-Mitchell S; Ramachandra N; Bernard L; Bhattacharyya S; Lopez R; Pradhan K; Giricz O; Ravipati G; Wong LF; Cole S; Bhagat TD; Feld J; Dhar Y; Bartenstein M; Thiruthuvanathan VJ; Wickrema A; Ye BH; Frank DA; Pellagatti A; Boultwood J; Zhou T; Kim Y; MacLeod AR; Epling-Burnette PK; Ye M; McCoon P; Woessner R; Steidl U; Will B; Verma A
J Clin Invest; 2018 Dec; 128(12):5479-5488. PubMed ID: 30252677
[TBL] [Abstract][Full Text] [Related]
56. Design of Novel IRAK4 Inhibitors Using Molecular Docking, Dynamics Simulation and 3D-QSAR Studies.
Bhujbal SP; He W; Hah JM
Molecules; 2022 Sep; 27(19):. PubMed ID: 36234844
[TBL] [Abstract][Full Text] [Related]
57. An IRAK1-PIN1 signalling axis drives intrinsic tumour resistance to radiation therapy.
Liu PH; Shah RB; Li Y; Arora A; Ung PM; Raman R; Gorbatenko A; Kozono S; Zhou XZ; Brechin V; Barbaro JM; Thompson R; White RM; Aguirre-Ghiso JA; Heymach JV; Lu KP; Silva JM; Panageas KS; Schlessinger A; Maki RG; Skinner HD; de Stanchina E; Sidi S
Nat Cell Biol; 2019 Feb; 21(2):203-213. PubMed ID: 30664786
[TBL] [Abstract][Full Text] [Related]
58. Clinical IRAK4 deficiency caused by homozygosity for the novel
Jia A; James E; Lu HY; Sharma M; Modi BP; Biggs CM; Hildebrand KJ; Chomyn A; Erdle S; Kular H; Turvey SE
Cold Spring Harb Mol Case Stud; 2020 Jun; 6(3):. PubMed ID: 32532880
[TBL] [Abstract][Full Text] [Related]
59. Molecular cloning, structural modeling, and expression analysis of MyD88 and IRAK4 of golden pompano (Trachinotus ovatus).
Qi Z; Sun B; Zhang Q; Meng F; Xu Q; Wei Y; Gao Q
Dev Comp Immunol; 2017 Sep; 74():19-24. PubMed ID: 28408332
[TBL] [Abstract][Full Text] [Related]
60. Myelodysplastic syndrome progression to acute myeloid leukemia at the stem cell level.
Chen J; Kao YR; Sun D; Todorova TI; Reynolds D; Narayanagari SR; Montagna C; Will B; Verma A; Steidl U
Nat Med; 2019 Jan; 25(1):103-110. PubMed ID: 30510255
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
